Leaving BNY Website

 

You are leaving the BNY Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2024 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
 

To learn more about DRs, please contact DRBrokerSolutions@bnymellon.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Back to Daily DR Market Summary

StreetAccount Summary - EU Market Recap: FTSE 100 +0.36% to 8223.34, DAX +0.69% to 18534.56, CAC40 +0.71% to 7627.13, STOXX 600 +0.60% to 519.51

Jul 11 ,2024

  • Synopsis:

    • European equity markets ended higher Thursday. Follows positive close on Wednesday. Real estate, utilities and constr/mtls outperform. Media , energy and tech the main laggards.

    • Markets higher following softer US June CPI reading, which came in cooler on both headline and core measures. Below-consensus weekly initial claims also helping ease worries about weakening growth. Data likely to further firm expectations for a September Fed rate cut (and possibly energize thoughts about a July move).

    • Macro focus in Europe on UK monthly activity data, which surprised on the upside. Latest monthly UK GDP estimate from the ONS showed +0.4% expansion in May versus consensus +0.2% and prior 0.0%. Source of upturn came from +0.2% expansion in industrial production, services output increased +0.3% and construction jumped +1.9%. While construction outperformed, services still the largest contributor to monthly GDP growth. Overnight, RICS house price balance missed but most agents now think the decline in UK house prices has now run its course. Comments from BoE's Mann and this week's remarks by chief economist Pill and MPC member Haskel dampens August rate cut expectations somewhat. Elsewhere, final German inflation in line with flash.

    • On the reporting front, out of DACHS region, Gerresheimer (GXI.GR) Q2 revenue missed; aEBITDA beat; confirmed FY guidance; expects material upturn in H2. Suedzucker (SZU.GR) Q1 EBIT, revenue missed; confirmed FY outlook. Barry Callebaut (BARN.SW) 9M revenue beat; reiterated FY guidance. In the UK, Hays (HAS.LN) LFL Net Fee Growth came short of expectations (15%) vs consensus (12%), John Wood Group prelim. H1 adjusted EBITDA miss, however reaffirmed FY and 2025 outlooks, RS Group (RS1.LN) said trading in Q1 was in line with expectations while Severn Trent (SVT.LN) financial performance for the year remains on track and continues to expect to perform in line with guidance. In the Nordics, Ambu (AMBU.B.DC) preliminary Q3 revenue beat, DNB Bank (DNB.NO) Q2 revenue, net income, CET1 all beat. Tryg (TRYG.DC) Q2 net income beat and pays dividend of DKK 1.95 per share. In other corporate news, Deutsche Lufthansa (LHA.GR) to undertake further austerity measures amid high costs and falling revenues.

    • On the M&A newsflow, press reports suggest Credit Agricole (ACA.FP) is in advanced talks to acquire Societe Generale (GLE.FP ) Hanseatic bank. Vitol launched €1.60/share mandatory tender offer for Saras (SRS.IM).

    • Looking ahead to tomorrow's EU econ-calendar, notable releases will include, amongst others, France and Spain Jun final CPI.

  • Digest:

    • Sectors - STOXX Europe 600:

      • Outperformers

        • Real Estate +2.03%, Utilities +1.68%, Construct & Mtls +1.62%, Retail +1.44%, Consumer Products and Services +1.44%, Financial Svcs +1.15%, Ind Goods & Svcs +0.90%, Travel & Leisure +0.76%, Personal Care Drug and Grocery Stores +0.64%

      • Underperformers

        • Media (0.57%), Oil&Gas (0.16%), Technology (0.13%), Telecom +0.13%, Basic Resources +0.23%, Autos & Parts +0.28%, Insurance +0.30%, Banks +0.45%, Food, Beverage and Tobacco +0.50%, Health Care +0.58%

    • Macro:

      • EU:

        • Italian airline deal wasn't cleared to help my boss: EU's Vestager -- Politico

      • UK:

        • Faster UK economy growth gives gift to new government -- Reuters

        • Starmer to begin reset of EU relations in meetings with Irish and French leaders -- Guardian

      • Germany:

        • Germany's debt brake and the art of fantasy budgeting -- Economist

        • Germans rage at 30pc tax break offered to immigrants -- Telegraph

      • France:

        • France Must Find €15B Annually to Meet EU Demands -- Bloomberg

        • France: like Germany without the money -- PWMnet

      • Italy:

        • Why backing superyachts might be a good idea for Italy -- FT

      • Spain:

        • Spain may not have new central bank governor by 18-Jul ECB meet, economy minister says -- Reuters

    • Company news:

      • Notable Gainers

        • +27.8% FARN.LN (Faron Pharmaceuticals £1.27, +0.28) -- positive FDA feedback

        • +27.3% RENX.LN (Renalytix £0.14, +0.03) -- collaboration

        • +15.6% KIT.NO (Kitron NOK38.72, +5.22) -- Q2 earnings

        • +10.5% MFEB.IM (MFE-MEDIAFOREUROPE €4.76, +0.45) -- JPMorgan upgrade

        • +9.7% PNN.LN (Pennon Group £6.87, +0.60) -- Ofwat publishes draft determinations for the 2024 price review; CFO to step down

        • +9.6% RS1.LN (RS Group plc £7.81, +0.70) -- trading update

        • +9.2% TTALO.FH (Terveystalo €9.43, +0.79) -- prelim Q2 earnings; raises FY guidance

        • +8.8% GFRD.LN (Galliford Try Holdings £2.93, +0.24) -- trading update

        • +6.3% PSM.GR (ProSiebenSat.1 Media €7.13, +0.43) -- JPMorgan upgrade

        • +6.3% ELO.NO (Elopak NOK39.60, +2.35) -- BNP Paribas Exane upgrade

        • +6.2% HUSQ.B.SS (Husqvarna SEK91.42, +5.32) -- Nordea upgrade

        • +6.1% INTRUM.SS (Intrum SEK34.66, +1.99) -- binding lock-up agreement with noteholders

        • +6.0% FIE.GR (Fielmann Group €43.95, +2.50) -- prelim H1 earnings

        • +5.9% DNB.NO (DNB Bank NOK217.00, +12.00) -- Q2 earnings

        • +5.8% IKA.LN (Ilika Plc £0.28, +0.02) -- FY earnings

        • +5.5% SMHN.GR (SÜSS MicroTec €68.50, +3.60) -- initiated buy at Deutsche Bank

        • +5.2% BONHR.NO (Bonheur NOK255.00, +12.50) -- Q2 earnings

        • +4.7% AMBU.B.DC (Ambu DKK138.20, +6.25) -- prelim Q3 earnings

        • +4.2% ADE.GR (Bitcoin Group €55.00, +2.20) -- FY earnings

        • +4.0% POLR.LN (Polar Capital Holdings £6.09, +0.23) -- trading update

        • +3.7% SVT.LN (Severn Trent £27.33, +0.98) -- Ofwat publishes draft determinations for the 2024 price review

        • +3.4% SDZ.SW (Sandoz Group CHF35.01, +1.16) -- Vontobel upgrade

        • +3.3% ALO.FP (Alstom €17.44, +0.55) -- resumed overweight at JPMorgan

        • +2.6% ALBPS.FP (Biophytis €0.58, +0.01) -- IND approval from the FDA to start its phase 2 OBA study

        • +2.6% UU.LN (United Utilities Group £10.99, +0.28) -- Ofwat publishes draft determinations for the 2024 price review

        • +2.0% BAYN.GR (Bayer AG €26.63, +0.52) -- FDA Fast Track and MHRA Innovation Passport designations for AB-1005

        • +1.6% DOCS.LN (Dr. Martens £0.75, +0.01) -- trading update

        • +0.4% AGR.AV (Agrana Beteiligungs €13.45, +0.05) -- Q1 earnings

      • Notable Decliners

        • -36.7% ACE.SS (Ascelia Pharma SEK5.95, -3.41) -- to carry out a rights issue of units in Aug; intends to raise ~SEK105M (gross)

        • -16.9% DOCM.SW (DocMorris CHF48.10, -9.79) -- prelim Q2 earnings

        • -12.9% QLINEA.SS (Q-linea SEK3.60, -0.53) -- Q2 earnings

        • -11.9% BARN.SW (Barry Callebaut CHF1,411.00, -191.00) -- 9M revenue

        • -8.7% SNI.NO (Stolt-Nielsen NOK433.00, -41.50) -- Q2 earnings

        • -6.2% BONEX.SS (BONESUPPORT HOLDING SEK270.20, -17.80) -- Q2 earnings

        • -6.1% BYIT.LN (Bytes Technology Group £4.94, -0.32) -- trading update

        • -5.5% TRST.LN (Trustpilot Group £2.21, -0.13) -- trading update

        • -4.0% SZU.GR (Suedzucker €13.07, -0.54) -- Q1 earnings

        • -1.8% EVT.GR (Evotec €9.24, -0.17) -- Deutsche Bank downgrade

        • -1.5% CAML.LN (Central Asia Metals £2.03, -0.03) -- operations update

        • -0.4% HPHA.GR (Heidelberg Pharma €2.54, -0.01) -- H1 earnings

    • EU companies reporting tomorrow:

      • Earnings:

        • DACHs: EMS-Chemie Holding (EMSN.SW)

        • Nordics:

          • Denmark: Topdanmark (TOP.DC)

          • Norway: Aker BP (AKRBP.NO), Storebrand (STB.NO), Aker Solutions (AKSO.NO), Protector Forsikring (PROT.NO), Entra (ENTRA.NO), Atea (ATEA.NO), Elkem (ELK.NO), Norwegian Air Shuttle (NAS.NO), Aker BioMarine (AKBM.NO), Norske Skog (NSKOG.NO), XXL (XXL.NO), Carasent (CARA.NO)

          • Sweden: Ericsson (ERIC.B.SS), Lifco (LIFCO.B.SS), Addtech (ADDT.B.SS), Axfood B (AXFO.SS), Avanza Bank (AZA.SS), Fortnox (FNOX.SS), Mycronic (MYCR.SS), Pandox (PNDX.B.SS), HMS Networks (HMS.SS), Vitec Software (VIT.B.SS), Addnode (ANOD.B.SS), OEM International (OEM.B.SS), Bravida (BRAV.SS), Granges (GRNG.SS), AQ Group (AQ.SS), Xvivo Perfusion (XVIVO.SS), Arjo (ARJO.B.SS), Norion Bank (NORION.SS), Inwido (INWI.SS), Nederman (NMAN.SS), Cloetta (CLA.B.SS), ITAB Shop Concept (ITAB.SS), TF Bank (TFBANK.SS), Duni (DUNI.SS), Lime Technologies (LIME.SS), Coor Service Management (COOR.SS), Proact IT (PACT.SS), Elanders (ELAN.B.SS), Plejd (PLEJD.SS), Exsitec (EXS.SS), Byggmax (BMAX.SS), FormPipe (FPIP.SS), CDON (CDON.SS), Balco (BALCO.SS), Netel (NETEL.SS), BE Group (BEGR.SS), Dedicare (DEDI.SS), Nelly (NELLY.SS), Lammhults Design (LAMM.B.SS)

  • Data:

    • Economics:

      • UK

        • May

          • Construction Output y/y +0.8% vs consensus (1.9%) and prior revised to (2.1%) from (3.3%)

          • Industrial Production y/y +0.4% vs consensus (0.3%) and prior revised to (0.7%) from (0.4%)

          • Trade Balance (£17.9B) vs consensus (£16.9B) and prior revised to (£19.4B) from (£19.6B)

        • Jun

          • NIESR monthly GDP tracker +0.6% vs consensus +0.5% and prior revised +0.8% from +0.7%

      • Germany June CPI y/y +2.2% vs consensus +2.2% and prior +2.2%

    • Markets:

      • WTI Crude (Aug 24): +$0.48 or +0.58% to $82.58

      • €-$ +0.0036 or +0.33% to 1.0868

      • £-$ +0.0063 or +0.49% to 1.2911

      • €-£ (0.0009) to 0.8420

      • S&P 500 (0.82%)

      • Performance year-to-date:

        • FTSE 100: +6.34%

        • DAX: +10.64%

        • CAC: +1.11%

        • MIB: +13.16%

        • Stoxx 600: +8.46%

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE